Search

Your search keyword '"Antacids administration & dosage"' showing total 896 results

Search Constraints

Start Over You searched for: Descriptor "Antacids administration & dosage" Remove constraint Descriptor: "Antacids administration & dosage"
896 results on '"Antacids administration & dosage"'

Search Results

1. Clinically important interactions of macrolides and tetracyclines with dietary interventions-a systematic review with meta-analyses.

2. Pharmacokinetics and Pharmacodynamics of a Fixed-Dose Combination of Esomeprazole and Magnesium Hydroxide Compared to the Enteric-Coated Esomeprazole.

3. Evaluation of Aluminum and Magnesium Absorption Following the Oral Administration of an Antacid Suspension Containing Magaldrate in Healthy Women Under Fed Conditions.

4. Oral Antacid Use Is Negatively Associated with Serum Prealbumin Levels in Japanese Individuals Undergoing Health Checkups.

5. Effect of Food, Crushing of Tablets, and Antacid Coadministration on Maribavir Pharmacokinetics in Healthy Adult Participants: Results From 2 Phase 1, Open-Label, Randomized, Crossover Studies.

6. Together or Apart? Revealing the Impact of Dietary Interventions on Bioavailability of Quinolones: A Systematic Review with Meta-analyses.

7. Lack of almagate interference in breath test results for Helicobacter pylori diagnosis (Almatest study).

8. Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study.

9. Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers.

10. Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next?

11. High prevalence of comorbidities and use of concomitant medication in treated people living with HIV in Germany - results of the BESIDE study.

12. Over-the-counter antacids linked to severe hypokalaemia in the context of threatened preterm labour.

13. Neutralization of Acidic Tumor Microenvironment (TME) with Daily Oral Dosing of Sodium Potassium Citrate (K/Na Citrate) Increases Therapeutic Effect of Anti-cancer Agent in Pancreatic Cancer Xenograft Mice Model.

14. Gastroprotective Therapy.

15. The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.

16. Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability.

17. Symptomatic response to GERDOFF® in patients with gastro-esophageal reflux disease and poor response to alginates: an exploratory, post-market, open-label study.

18. Chewable Antacid Tablets: Are Disintegration Tests Relevant?

19. Reno-protective effects of oral alkalizing agents in chronic kidney disease with aciduria: protocol for a randomized cohort study.

20. Effect of an Al/Mg Hydroxide Antacid and Food on the Pharmacokinetics of Dexibuprofen.

21. Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study).

22. Quality of life and gastric acid-suppression medication 20 years after laparoscopic fundoplication.

23. Alkalinizing Agents: A Review of Prescription, Over-the-Counter, and Medical Food Supplements.

24. A Potassium-Competitive Acid Blocker-Based Regimen as Second-Line Therapy Improves Helicobacter pylori Eradication.

25. Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases.

26. A Proposal of Conducting Bioequivalence Trials with Gastric pH Modulators for Two Oral Formulations Demonstrating Different Dissolution Profiles at Elevated pH.

27. Allicin as add-on therapy for Helicobacter pylori infection: A systematic review and meta-analysis.

28. Concomitant use of capecitabine and proton pump inhibitors - Is it safe?

29. Retrospective Analysis Confirms Tetracycline Quadruple as Best Helicobacter pylori Regimen in the USA.

30. Evaluation of an Eight-Week Whole-Food Plant-Based Lifestyle Modification Program.

31. A Multidisciplinary Approach to Incorporate Bedside Nurses into Antimicrobial Stewardship and Infection Prevention.

32. Clostridium difficile infection associated with bismuth-based quadruple therapy (Pylera ® ) for Helicobacter pylori eradication.

33. [Comparison of the traditional triple and a new bismuth-containing quadruple therapy in the first-line eradication of Helicobacter pylori ].

34. Warnings on the safety of quinolones: Should Helicobacter pylori treatment prescriptions be modified?

35. Can the treatment duration be shortened in bismuth-containing therapies for Helicobacter pylori eradication?

36. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin.

37. Acid Suppression in Neonates: Friend or Foe?

38. Oral Methods of Urinary Alkalinization for High-dose Methotrexate Administration: Alternatives to Intravenous Sodium Bicarbonate During a Critical Drug Shortage.

39. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.

40. Formulation, optimization, and evaluation of raft-forming formulations containing Nizatidine.

41. Complications following removal of oesophageal foreign bodies: a retrospective review of 349 cases.

42. A physiologically-based pharmacokinetic model adequately predicted the human pharmacokinetic profiles of YH4808, a novel K + -competitive acid blocker.

43. [Alginate on demand as add-on for patients with gastro-oesophageal reflux disease and insufficient PPI effect].

44. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease.

45. 72-Year-Old Woman With Fatigue, Confusion, and Severe Acute Renal Failure.

46. Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects.

47. Gaviscon® Advance alone versus co-prescription of Gaviscon® Advance and proton pump inhibitors in the treatment of laryngopharyngeal reflux.

48. 14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial.

49. Modern achievements in the diagnosis and treatment of the refractory gastroesophageal reflux disease.

50. Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection.

Catalog

Books, media, physical & digital resources